Beth C. Seidenberg - May 9, 2023 Form 4 Insider Report for ACELYRIN, Inc. (SLRN)

Role
Director, 10%+ Owner
Signature
/s/ Mina Kim, Attorney-in-fact
Stock symbol
SLRN
Transactions as of
May 9, 2023
Transactions value $
$23,580,000
Form type
4
Date filed
5/11/2023, 09:13 PM
Previous filing
May 4, 2023
Next filing
May 12, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLRN Common Stock Conversion of derivative security +8.54M 8.54M May 9, 2023 See footnote F1, F2
transaction SLRN Common Stock Purchase $22.5M +1.25M +14.64% $18.00 9.79M May 9, 2023 See footnote F2, F3
transaction SLRN Common Stock Purchase $1.08M +60K $18.00 60K May 9, 2023 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLRN Series A Redeemable Convertible Preferred Stock Conversion of derivative security -4.06M -100% 0 May 9, 2023 Common Stock 4.06M See footnote F2, F5, F6
transaction SLRN Series B Redeemable Convertible Preferred Stock Conversion of derivative security -2.45M -100% 0 May 9, 2023 Common Stock 2.45M See footnote F2, F5, F6
transaction SLRN Series C Redeemable Convertible Preferred Stock Conversion of derivative security -2.04M -100% 0 May 9, 2023 Common Stock 2.04M See footnote F2, F5, F6
transaction SLRN Director Stock Option (right to buy) Other $0 -23.2K -100% $0.00* 0 May 9, 2023 Class A Common Stock 23.2K $18.00 Direct F6, F7
transaction SLRN Director Stock Option (right to buy) Other $0 +23.2K $0.00 23.2K May 9, 2023 Common Stock 23.2K $18.00 Direct F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of Common Stock received upon conversion of shares of the reported series of preferred stock on a one-for-one basis without payment of further consideration.
F2 Shares held directly by Westlake BioPartners Fund II, L.P., or Westlake Fund II. Westlake BioPartners GP II, LLC, or Westlake GP II, is the general partner of Westlake Fund II. Westlake GP II may be deemed to have sole voting and dispositive power with regard to the shares held directly by Westlake Fund II. The Reporting Person and Sean E. Harper are the Managing Directors of Westlake GP II and share voting and dispositive power over the shares held by Westlake Fund II, each of whom disclaims beneficial ownership of the shares held by Westlake Fund II except to the extent of such person's pecuniary interest therein, if any.
F3 Represents shares of Common Stock purchased in the Issuer's initial public offering of Common Stock (the "IPO").
F4 Represents shares of Common Stock purchased through a directed share program in the IPO.
F5 Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock.
F6 Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.
F7 1/36 of the shares subject to the option vest on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.